Theranica Bio-Electronics Ltd. news
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the appointment of Scott Serota to its Board of Directors.
"Over the course of the past few decades, which I have dedicated to enabling patients of various medical conditions access to new treatments, I developed passion for supporting the advancement of breakthrough ther
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, mult
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning a new HCPCS Level II code K1023 "Distal Transcutaneous Electrical Nerve Stimulator, Stimulates Peripheral Nerve
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced&
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today that a new peer-reviewed study published in Pain and Therapy demonstrates the efficacy of Nerivio® in treating menstrual migraine.
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA.
"We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital therapeutics such as Nerivio," s
Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the treatment of adolescents